Friday 23 April 2021
Home      All news      Contact us      RSS      India
orissadiary.com - 2 month ago

Phase 3 Clinical Trial of COVAXIN, developed by ICMR Bharat Biotech, shows 81% efficacy

New Delhi: Phase 3 results of the COVAXIN, developed by Indian Council of Medical Research (ICMR)in partnership with Bharat BiotechInternational Limited (BBIL),has shown an interim vaccine efficacy of 81% in preventing Covid-19. The Phase 3 trial,jointly initiated by ICMR and BBIL in mid-November 2020,was conducted in a total of 25,800 individualsacross 21 sites. The interim efficacy [ ]


Latest News
Hashtags:   

Phase

 | 

Clinical

 | 

Trial

 | 

COVAXIN

 | 

developed

 | 

Bharat

 | 

Biotech

 | 

shows

 | 

efficacy

 | 

Sources